Publisher
Springer Science and Business Media LLC
Reference6 articles.
1. Biolato M, Bianco A, Lucchini M, Gasbarrini A, Mirabella M, Grieco A (2021) The disease-modifying therapies of relapsing-remitting multiple sclerosis and liver injury: a narrative review. CNS Drugs. https://doi.org/10.1007/s40263-021-00842-9
2. Velișcu EM, Liguori V, Anatriello A, Maniscalco GT, Cantone A, Di Costanzo L, Stefanelli P, Scavone C, Capuano A (2023) Hepatobiliary adverse reactions during treatment with cladribine: analysis of data from the european spontaneous reporting system. Pharmaceuticals (Basel). https://doi.org/10.3390/ph16081071
3. Zanetta C, Rocca MA, Meani A, Martinelli V, Ferrè L, Moiola L, Filippi M (2023) Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study. J Neurol. https://doi.org/10.1007/s00415-023-11700-7
4. European Medicines Agency (EMA). Direct healthcare professional communication (DHPC): Mavenclad (cladribine)—risk of serious liver injury and new recommendations about liver function monitoring. First published: 14/02/2022
5. Meunier L, Larrey D (2023) Hepatotoxicity of drugs used in multiple sclerosis, diagnostic challenge, and the role of HLA genotype susceptibility. Int J Mol Sci. https://doi.org/10.3390/ijms24010852